Citius Pharmaceuticals (CTXR) Current Leases (2019 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Current Leases came in at $171495.0 in Q1 2026, up 18.19% YoY from $145098.0 in Q1 2025, and up 15.87% on a QoQ basis from $148006.0 in Q4 2025.
Citius Pharmaceuticals (CTXR) Current Leases (2019 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 8 years of Current Leases data on file, last reported at $171495.0 in Q1 2026.
- Quarterly Current Leases rose 18.19% year-over-year to $171495.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $171495.0 (up 18.19% YoY) and the FY2025 annual result came in at $88348.0, down 63.42% from the prior year.
- Current Leases climbed to $171495.0 in Q1 2026, from $148006.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $241547.0 in Q3 2024 to a low of $88348.0 in Q3 2025.
- A 5-year average of $189398.7 and a median of $202178.0 in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2025 — Current Leases sank 63.42% — and 2026, when it grew 18.19%.
- Tracing CTXR's Current Leases over 5 years: stood at $202178.0 in 2022, then advanced by 10.79% to $224000.0 in 2023, then declined by 8.67% to $204569.0 in 2024, then fell by 27.65% to $148006.0 in 2025, then increased by 15.87% to $171495.0 in 2026.
- The last three Current Leases figures came in at $171495.0 (Q1 2026), $148006.0 (Q4 2025), and $88348.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | - |
| 10 | Citius Pharmaceuticals | 15.96 Mn | 15.96 Mn | 1.00 Mn | 176,170.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 171,495.00 |
| Dec 31, 2025 | 148,006.00 |
| Sep 30, 2025 | 88,348.00 |
| Jun 30, 2025 | 114,694.00 |
| Mar 31, 2025 | 145,098.00 |
| Dec 31, 2024 | 204,569.00 |
| Sep 30, 2024 | 241,547.00 |
| Jun 30, 2024 | 235,581.00 |
| Mar 31, 2024 | 229,733.00 |
| Dec 31, 2023 | 224,000.00 |
| Sep 30, 2023 | 218,380.00 |
| Jun 30, 2023 | 212,871.00 |
| Mar 31, 2023 | 207,471.00 |
| Dec 31, 2022 | 202,178.00 |
| Sep 30, 2022 | 196,989.00 |
| Jun 30, 2022 | 191,902.00 |
| Mar 31, 2022 | 186,916.00 |
| Dec 31, 2021 | 182,028.00 |
| Sep 30, 2021 | 177,237.00 |
| Jun 30, 2021 | 172,540.00 |